Hematological Findings in 20 Members of the Family
Subject . | Hgb g/L . | RBC × 1012/L . | Hcrit% . | WBC × 109/L . | Platelets × 109/L . | S-EPO mU/mL . | EPOR Mutation . |
---|---|---|---|---|---|---|---|
Affected | |||||||
II11 | 178 | 5.9 | 57 | ||||
II12 | ≈270 | 6.6 | 9.3 | 89 | |||
III15 | ≈245 | 7.2 | 73 | 5.7 | |||
III16 | ≈202 | 5.7 | 78 | 4.1 | |||
III17 | 195 | 6.0 | 55 | 4.2 | 137 | 4 | + |
III18 | 169 | 5.3 | 50 | 7.2 | 164 | 3 | + |
III19 | 160 | 6.7 | 51 | 3.6 | 209 | 7 | + |
IV7 | 172 | 5.5 | 50 | 9.7 | 116 | 6 | + |
IV8 | 178 | 5.6 | 52 | 7.4 | 140 | 3 | + |
IV11 | 173 | 5.2 | 51 | 7.9 | 215 | 4 | + |
V2 | 152 | 5.2 | 44 | 8 | + | ||
Unaffected | |||||||
II2 | 154 | 4.5 | |||||
II10 | 134 | ||||||
IV9 | 149 | 4.7 | 43 | 5.2 | 186 | 12 | − |
IV10 | 139 | 4.6 | 40 | 7.4 | 212 | 6 | − |
IV12 | 126 | 4.2 | 38 | 6.2 | 259 | 19 | − |
IV13 | 158 | 5.2 | 46 | 7.1 | 298 | 9 | − |
V1 | 135 | 4.9 | 40 | 18 | − | ||
V3 | 125 | 4.4 | 36 | 7.5 | 446 | 13 | − |
V4 | 118 | 4.2 | 33 | 6.4 | 283 | 12 | − |
Subject . | Hgb g/L . | RBC × 1012/L . | Hcrit% . | WBC × 109/L . | Platelets × 109/L . | S-EPO mU/mL . | EPOR Mutation . |
---|---|---|---|---|---|---|---|
Affected | |||||||
II11 | 178 | 5.9 | 57 | ||||
II12 | ≈270 | 6.6 | 9.3 | 89 | |||
III15 | ≈245 | 7.2 | 73 | 5.7 | |||
III16 | ≈202 | 5.7 | 78 | 4.1 | |||
III17 | 195 | 6.0 | 55 | 4.2 | 137 | 4 | + |
III18 | 169 | 5.3 | 50 | 7.2 | 164 | 3 | + |
III19 | 160 | 6.7 | 51 | 3.6 | 209 | 7 | + |
IV7 | 172 | 5.5 | 50 | 9.7 | 116 | 6 | + |
IV8 | 178 | 5.6 | 52 | 7.4 | 140 | 3 | + |
IV11 | 173 | 5.2 | 51 | 7.9 | 215 | 4 | + |
V2 | 152 | 5.2 | 44 | 8 | + | ||
Unaffected | |||||||
II2 | 154 | 4.5 | |||||
II10 | 134 | ||||||
IV9 | 149 | 4.7 | 43 | 5.2 | 186 | 12 | − |
IV10 | 139 | 4.6 | 40 | 7.4 | 212 | 6 | − |
IV12 | 126 | 4.2 | 38 | 6.2 | 259 | 19 | − |
IV13 | 158 | 5.2 | 46 | 7.1 | 298 | 9 | − |
V1 | 135 | 4.9 | 40 | 18 | − | ||
V3 | 125 | 4.4 | 36 | 7.5 | 446 | 13 | − |
V4 | 118 | 4.2 | 33 | 6.4 | 283 | 12 | − |
“Affected,” those with either clinical evidence of erythrocytosis or presence of an EPOR mutation or both. “Unaffected,” no clinical evidence of erythrocytosis or EPOR mutation. Normal hematological parameters are: hemoglobin (Hgb), males 122-166 g/L, females 113-153 g/L; red blood cell count (RBC), males 4.1-5.4 × 1012/L, females 3.7-4.9 × 1012/L; hematocrit (Hcrit), males 39% to 49%, females 37% to 44%; white blood cell count (WBC), 4.0-10.0 × 109/L; platelets, 125-340 × 109/L; S-EPO, 5-19 mU/mL.